Italia markets close in 5 hours 42 minutes

Evolus, Inc. (0K16.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
9,09-2,17 (-19,27%)
Al 05:43PM BST. Mercato aperto.
Schermo intero
Chiusura precedente11,26
Aperto9,09
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno9,09 - 9,09
Intervallo di 52 settimane9,09 - 9,09
Volume1.070
Media VolumeN/D
Capitalizzazione2,334M
Beta (5 anni mensile)1,93
Rapporto PE (ttm)N/D
EPS (ttm)-1,30
Prossima data utili31 ott 2022 - 04 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Evolus Announces Participation in November Investment Conferences

    NEWPORT BEACH, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in two investment conferences in November. Event:Stifel 2021 Virtual Healthcare Conference Date:Tuesday, November 16, 2021 Time:2:40 pm ET Event:Evercore ISI 4th Annual HealthCONx Virtual Conference Date:Tuesday, November 30, 2021 Ti

  • GlobeNewswire

    Evolus Reports Third Quarter 2021 Results and Provides Business Update

    Record Quarter: U.S. Net Revenue Grew 58% Year-over-Year to $26.7 Million $107.8 Million Cash Position at Quarter-EndInitiated Jeuveau® “Extra Strength” Phase II Clinical Program to Demonstrate Extended Duration NEWPORT BEACH, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today reported financial results for the third quarter ended September 30, 2021 and provided a

  • GlobeNewswire

    Evolus Initiates Phase II Program with “Extra Strength” Dose for Extended Duration

    Program Designed to Offer Consumers an “Extra Strength” Dosing OptionEvolus is Uniquely Positioned to Capitalize on this Opportunity with the Company’s Aesthetics-Only Strategy and Jeuveau® Product PrecisionFirst Patient Enrollment Expected in Q1 2022; Expected Completion in 1H 2023 NEWPORT BEACH, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it